Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VIKAS GUPTA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1770526964
CMS profile
307475
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,877.78

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,877.78 86

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VIKAS GUPTA

NPI 1770526964 · CMS profile ID 307475

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770526964?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VIKAS GUPTA, NPI 1770526964, CMS profile ID 307475. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770526964?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). VIKAS GUPTA, NPI 1770526964, CMS profile ID 307475. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770526964?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
VIKAS GUPTA, NPI 1770526964, CMS profile ID 307475, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1770526964?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $1,877.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $26.7107/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044578081 CMS
Amgen Inc. $17.8006/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020188427 CMS
Regeneron Healthcare Solutions, Inc. $15.7406/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999198925 CMS
Gilead Sciences, Inc. $23.6806/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025684369 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $32.2906/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997124413 CMS
Pharmacyclics LLC, An AbbVie Company $24.0806/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998286529 CMS
AstraZeneca Pharmaceuticals LP $21.4706/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015433915 CMS
Genentech USA, Inc. $21.6806/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040591097 CMS
Incyte Corporation $24.9706/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044425807 CMS
Novartis Pharmaceuticals Corporation $16.7806/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992019619 CMS
Daiichi Sankyo Inc. $29.7006/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006401517 CMS
Stemline Therapeutics Inc. $17.7105/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040041555 CMS
Amgen Inc. $17.6405/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020188423 CMS
Kite Pharma, Inc. $15.5005/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025269537 CMS
AstraZeneca Pharmaceuticals LP $17.8905/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015657331 CMS
AstraZeneca Pharmaceuticals LP $21.9705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016234201 CMS
Amgen Inc. $15.7505/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020694869 CMS
Seagen Inc. $21.1205/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995707187 CMS
AstraZeneca Pharmaceuticals LP $83.0205/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015678209 CMS
Daiichi Sankyo Inc. $22.2005/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006430547 CMS
Gilead Sciences, Inc. $24.2205/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025665199 CMS
Merck Sharp & Dohme LLC $26.8205/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048565045 CMS
Kyowa Kirin, Inc. $18.3405/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027028261 CMS
Novartis Pharmaceuticals Corporation $17.8404/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992019571 CMS
Janssen Biotech, Inc. $18.1504/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988720491 CMS
Merck Sharp & Dohme LLC $22.9904/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048824399 CMS
Novartis Pharmaceuticals Corporation $12.7904/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992019603 CMS
Regeneron Healthcare Solutions, Inc. $14.2304/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999198921 CMS
Amgen Inc. $22.8504/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020188415 CMS
Gilead Sciences, Inc. $24.4903/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025655909 CMS
SERVIER PHARMACEUTICALS LLC $19.9503/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055095071 CMS
Merck Sharp & Dohme LLC $22.2003/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048565047 CMS
Novartis Pharmaceuticals Corporation $16.7103/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992019595 CMS
Gilead Sciences, Inc. $24.3702/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025660173 CMS
Incyte Corporation $19.1301/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044425637 CMS
GlaxoSmithKline, LLC. $22.0501/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001502859 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $87.00 1
PY2021 $61.92 2
PY2022 $260.79 8
PY2023 $1,877.78 86
PY2024 $2,870.30 143
PY2025 $1,951.53 91

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $46,498.54 25
PY2021 Principal investigator $85,430.19 51
PY2020 Principal investigator $143,067.51 31
PY2019 Principal investigator $18,168.75 35

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $75.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225063
Principal investigator 1 Incyte Corporation $600.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225065
Principal investigator 1 Incyte Corporation $300.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225067
Principal investigator 1 Incyte Corporation $4,500.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225069
Principal investigator 1 Incyte Corporation $1,500.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225071
Principal investigator 1 Incyte Corporation $1,000.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225073
Principal investigator 1 Incyte Corporation $2,250.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225075
Principal investigator 1 Incyte Corporation $699.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225077
Principal investigator 1 Incyte Corporation $466.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225079
Principal investigator 1 Incyte Corporation $1,500.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225081
Principal investigator 1 Incyte Corporation $75.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225083
Principal investigator 1 Incyte Corporation $75.00 10/12/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225085
Principal investigator 1 Incyte Corporation $16,631.40 09/28/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225059
Principal investigator 1 Incyte Corporation $53.37 07/11/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225061
Principal investigator 1 Incyte Corporation $7,433.00 04/22/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225013
Principal investigator 1 Incyte Corporation $233.00 04/22/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225015
Principal investigator 1 Incyte Corporation $662.00 04/22/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225017
Principal investigator 1 Incyte Corporation $985.53 04/22/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225019
Principal investigator 1 Incyte Corporation $176.00 04/22/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225021
Principal investigator 1 Incyte Corporation $3,641.40 04/18/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225011
Principal investigator 1 Incyte Corporation $0.36 04/08/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225023
Principal investigator 1 Incyte Corporation $0.36 04/08/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225049
Principal investigator 1 Incyte Corporation $0.36 04/08/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225051
Principal investigator 1 Incyte Corporation $0.36 04/08/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225053
Principal investigator 1 Incyte Corporation $3,641.40 01/26/2022 Non-covered Recipient Entity
CCCNV SUNSET
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 905225009